Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?
NCT ID: NCT02903082
Last Updated: 2019-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
68 participants
OBSERVATIONAL
2015-04-30
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
NCT05110937
Myeloid-derived Suppressor Cells in Sepsis
NCT03540797
Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock
NCT02062970
Expression Profiles of Integrin αDβ2 on Neutrophils in Sepsis
NCT04103281
Monitoring Mitophagy In Myeloid Cells Upon Intensive Care
NCT05040503
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
Residue of blood further to NFS
Bone marrow collected during myelogram routinely performed during hospitalization in ICU
Control
10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
Residue of blood further to preoperative workup
Bone marrow collected during a myelogram carried out for hematological pathology workup
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Residue of blood further to NFS
Residue of blood further to preoperative workup
Bone marrow collected during a myelogram carried out for hematological pathology workup
Bone marrow collected during myelogram routinely performed during hospitalization in ICU
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with two criteria of systemic inflammatory response syndrome and one of the four following criteria within 24 hours of hospitalization in ICU:
* Lactate \>4 mmol/L
* PaO2 / FiO2 \<200 in the presence of lung disease as infectious source
* Vasopressor: adrenaline or noradrenaline ≥0.25 µg/kg/min for at least 6 hours to maintain a systolic blood pressure ≥90 mmHg or mean arterial pressure ≥65 mmHg
* Thrombocytopenia linked to sepsis with platelet count \<100,000 / ml or a decrease ≤50% within 48 hours
Exclusion Criteria
* progressive solid cancer
* HIV infection
* History of blood or inflammatory disease
* long-term immunosuppressive treatment
* Prior episode of Sepsis in the previous month
* Chronic Dialysis Patient
* Patient under guardianship
* Patient not affiliated with a social security system
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Limoges
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de LIMOGES
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I16019 (MDSC)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.